MTR 0.00% 33.0¢ metal tiger plc


  1. 2,839 Posts.
    MTR Press Release,

    Meditech says safety trial of anti-cancer drug successful
    MELBOURNE, May 16 AAP - Drug development company Meditech
    Research Ltd will move towards a Phase II trial of anti-cancer drug
    HyDox after the success of the Phase 1 safety trial.
    The company said patients with advanced stages of cancer had
    been safely administered progressively higher doses of HyDox in the
    Phase 1 trial.
    "This allows Meditech to begin planning design of its Phase II
    clinical trial of HyDox," the company said.
    Meditech said results of the Phase I trial were expected to be
    available to shareholders by the end of June.
    Meditech shares were 1.5 cents higher at 36.5 cents at 1314 AEST

watchlist Created with Sketch. Add MTR (ASX) to my watchlist
(20min delay)
Mkt cap ! $55.90M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 3124 32.0¢

Sellers (Offers)

Price($) Vol. No.
33.0¢ 1827 1
View Market Depth
Last trade - 16.12pm 18/05/2022 (20 minute delay) ?
MTR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.